Unjoni Ewropea - Malti - EMA (European Medicines Agency)

shire pharmaceutical contracts limited - epoetin delta - kidney failure, chronic; anemia - preparazzjonijiet antianemiċi - dynepo huwa indikat għall-kura ta 'anemija sintomatika assoċjata ma' insuffiċjenza renali kronika (crf) f'pazjenti adulti. jista 'jintuża f'pazjenti fuq id-dijaliżi u f'pazjenti mhux fuq id-dijalisi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - karċinoma, pulmun mhux taċ-Ċellula Żgħira - antineoplastika u immunomodulanti l-aġenti, antikorpi monoklonali - nivolumab bms huwa indikat għall-kura ta 'kanċer tal-pulmun taċ-ċelluli mhux żgħar tat-tip squamous lokalment avvanzat jew metastatiku (nsclc) wara kimoterapija minn qabel fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

servier (ireland) industries ltd - agomelatine - disturb depressiv, maġġur - psychoanaleptics, - trattament ta 'episodji depressivi maġġuri fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

abbott laboratories ltd. - adalimumab - spondylitis, ankylosing; arthritis, rheumatoid; arthritis, psoriatic; crohn disease - immunosoppressanti - rewmatika arthritistrudexa flimkien ma ' methotrexate, huwa indikat għall -: - trattament ta moderata sa severa, artrite rewmatika attiva f'pazjenti adulti, meta r-rispons li jimmodifikaw il-marda anti-rewmatiċi-mediċini inkluż methotrexate, ma jkunx adegwat. il-kura ta attiva u progressiva severa, artrite rewmatika fl-adulti li ma kienux ittrattati qabel b'methotrexate. trudexa jista 'jingħata waħdu f'każ ta' intolleranza għal methotrexate jew meta trattamenti fit-tul b'methotrexate mhux adattat. intwera li trudexa jnaqqas ir-rata ta 'progressjoni tal-ħsara fil-ġogi kif imkejjel permezz ta' x-ray, u li jtejjeb il-funzjoni fiżika, meta jingħata flimkien ma ' methotrexate. psorjatika arthritistrudexa huwa indikat għall-kura tas-sustanza attiva u progressiva artrite psorjatika fl-adulti meta r-rispons għall-preċedenti li jimmodifikaw il-marda anti-rewmatiċi terapija bil-mediċina kienet inadegwata. ankylosing spondylitistrudexa huwa indikat għall-kura ta ' adulti li jbatu minn ankylosing spondylitis attiva li kellhom rispons mhux adekwat għat-terapija. crohn diseasetrudexa huwa indikat għall-kura ta ' marda ta'crohn attiva, f'pazjenti li ma kellhomx rispons minkejja sħiħ u adegwat matul it-terapija b'xi corticosteroid u/jew immunosoppressanti; jew li huma intolleranti għal, jew li jkollhom kontra-indikazzjonijiet mediċi għal terapiji bħal dawn. għall-kura tal-bidu, trudexa għandu jingħata flimkien ma ' corticosteroids. trudexa jista 'jingħata bħala monoterapija f'kaz ta' intolleranza għall-corticosteroids jew meta titkompla l-kura bil-corticosteroids m'hijiex adattata (ara sezzjoni 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - avibactam sodium, ceftazidime pentahydrate - pneumonia, bacterial; soft tissue infections; pneumonia; urinary tract infections; gram-negative bacterial infections - antibatteriċi għal użu sistemiku, - zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:complicated intra-abdominal infection (ciai)complicated urinary tract infection (cuti), including pyelonephritishospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap)treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. zavicefta is also indicated for the treatment of infections due to aerobic gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - iebes capsuleszerit huwa indikat flimkien ma ' prodotti mediċinali antiretrovirali oħra għat-trattament ta infettati bl-hiv pazjenti adulti u pazjenti pedjatriċi ('l fuq minn l-età ta'tliet xhur) biss meta l-mediċini antiretrovirali oħra ma jistgħux jintużaw. it-tul tat-terapija b'zerit għandha tiġi limitata għall-iqsar żmien possibbli. trab għall-ħalq solutionzerit huwa indikat flimkien ma ' prodotti mediċinali antiretrovirali oħra għat-trattament ta infettati bl-hiv pazjenti adulti u pazjenti pedjatriċi (mit-twelid) biss meta l-mediċini antiretrovirali oħra ma jistgħux jintużaw. it-tul tat-terapija b'zerit għandha tiġi limitata għall-iqsar żmien possibbli.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - antibatteriċi għal użu sistemiku, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

immunocore ireland limited - tebentafusp - uveal neoplasms - aġenti antineoplastiċi - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - aġenti antineoplastiċi - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

amgen europe b.v. - talimogene laherparepvec - melanoma - aġenti antineoplastiċi - imlygic huwa indikat għat-trattament ta ' l-adulti bl-melanoma unresectable li huwa metastatic reġjonalment jew klassi (stadju iiib, iiiĊ u ivm1a) bl-ebda għadma, moħħ, tal-pulmun jew marda vixxri oħra.